Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.73 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | GRK6 | P43250 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7121384 | 0.92 | KEAP1 (0.86) | KEAP1NFE2L2ALDH1A1MAPTLMNA | |
| SCHEMBL5866501 | 0.90 | KEAP1 (0.69) | KEAP1NFE2L2ALDH1A1MAPTLMNA | |
| SCHEMBL30268664 | 0.86 | KEAP1 (0.70) | KEAP1NFE2L2ALDH1A1MAPTLMNA | |
| SCHEMBL3605803 | 0.86 | KEAP1 (0.75) | KEAP1NFE2L2ALDH1A1MAPTLMNA | |
| SCHEMBL4930390 | 0.85 | KEAP1 (1.00) | KEAP1NFE2L2ALDH1A1MAPTLMNA | |
| SCHEMBL581124 | 0.82 | ALDH1A1 (1.00) | ALDH1A1MAPTLMNAL3MBTL1NPC1 | |
| SCHEMBL8279098 | 0.81 | ALDH1A1 (0.70) | ALDH1A1MAPTLMNAL3MBTL1NPC1 | |
| SCHEMBL678363 | 0.81 | ALDH1A1 (0.70) | KEAP1NFE2L2ALDH1A1MAPTLMNA | |
| SCHEMBL5729760 | 0.81 | ALDH1A1 (0.70) | KEAP1NFE2L2ALDH1A1MAPTLMNA | |
| SCHEMBL6937072 | 0.79 | NPC1 (0.71) | KEAP1NFE2L2ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | claimed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | claimed |
| EP-3328832-B1 | FUCOSIDASE INHIBITORS | HORIZON ORPHAN LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10308607-B2 | Fucosidase inhibitors | HORIZON ORPHAN LLC (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190077756-A1 | FUCOSIDASE INHIBITORS | HORIZON ORPHAN LLC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20170029376-A1 | FUCOSIDASE INHIBITORS | RAPTOR PHARMACEUTICALS INC. (US) | 2017-02-02 | — | — | US | disclosed |
| WO-2017019925-A1 | FUCOSIDASE INHIBITORS | RAPTOR PHARMACEUTICALS INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-8034944-B2 | Benzofluoranthene compound and organic light-emitting device using the compound | CANON KABUSHIKI KAISHA (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034944-B2 | Benzofluoranthene compound and organic light-emitting device using the compound | CANON KABUSHIKI KAISHA (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20090278118-A1 | BENZOFLUORANTHENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090278118-A1 | BENZOFLUORANTHENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2009-11-12 | — | — | US | disclosed |
| WO-2008078824-A1 | BENZOFLUORANTHENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2008-07-03 | — | — | WO | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029376-A1 | FUCOSIDASE INHIBITORS | FUCA1, FUCA2, ENGASE | KEAP1 393/4885NFE2L2 2617/4885ALDH1A1 588/4885 |
| US-20190077756-A1 | FUCOSIDASE INHIBITORS | FUCA1, FUCA2, ENGASE | KEAP1 393/4885NFE2L2 2617/4885ALDH1A1 588/4885 |
| US-20090278118-A1 | BENZOFLUORANTHENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND | XDH, XPO6, PAX3 | KEAP1 2501/4885NFE2L2 135/4885ALDH1A1 1092/4885 |
| US-10308607-B2 | Fucosidase inhibitors | FUCA1, FUCA2, ENGASE | KEAP1 393/4885NFE2L2 2617/4885ALDH1A1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.